New RNA-Based Breakthroughs in Alzheimer's Disease Diagnosis and Therapeutics

Pharmaceutics. 2021 Sep 3;13(9):1397. doi: 10.3390/pharmaceutics13091397.

Abstract

Dementia is described as the fifth leading cause of death worldwide and Alzheimer's disease (AD) is recognized as the most common, causing a huge impact on health costs and quality of patients' lives. The main hallmarks that are commonly associated with the pathologic process are amyloid deposition, pathologic Tau phosphorylation and neurodegeneration. It is still unclear how these events are linked to the disease progression, due to the complex pathologic mechanisms. Nevertheless, several hypotheses have been proposed for a better understanding of AD. The AD diagnosis is performed by using a combination of several tools to detect β-amyloid peptide (Aβ) deposits and modifications in cognitive performance, sometimes being expensive and invasive. In the treatment field, there is still an absence of effective treatments to delay or stop the progression of the disease, with most of the approved drugs used to relieve symptoms, and all of them with significant adverse side effects. Considering all limitations, the need to establish new and more effective diagnostic and therapeutic strategies becomes clear. This review aims not only to describe the disease and its impact but also to collect the currently available diagnostic and therapeutic strategies, highlighting new promising RNA-based strategies for AD.

Keywords: Alzheimer’s disease; RNA-based therapeutics; amyloid hypothesis; dementia; diagnosis.

Publication types

  • Review